Agency notice: CDC seeks comment on proposed West Nile antibody profile
Federal · applicability depends on the document
The CDC has opened a docket for comments and suggestions on the proposed profile.
The profile aims to set minimal and optimal attributes for a West Nile virus monoclonal antibody product for pre- or post-exposure prevention in patients at higher risk of severe disease.
Based on the linked record from Federal Register ↗. Our reporting and verification standards.
Source, dates and supporting record
- Source published
- Nov 16, 2026
- Last checked
- Nov 18, 2026, 4:55 PM EST
- Record status
- Agency notice
- Comment deadline
- Jan 15, 2027
Supporting excerpts
The Centers for Disease Control and Prevention (CDC) in the Department of Health and Human Services (HHS) announces the opening of a docket to obtain comment on the proposed Target Product Profile for Monoclonal Antibodies for West Nile Virus Disease Prevention.
This Request for Information (RFI) invites comments and suggestions on the proposed target product profile.
The objective of the target product profile is to describe key minimal and optimal attributes for a West Nile virus monoclonal antibody product that can be provided to patients at higher risk for severe West Nile virus disease as pre- or post- exposure prophylaxis.
Original source text
Source wording and its time zone may differ. Date-only dates are preserved. Timestamps here use Eastern Time. Evidence version: ac7c0bc9979a14036d10ebdeb4431187da9a841bd96c461d4b7ba1a4350ac57c
Source guidance
Original guidance from the issuing source. For current warnings and instructions, consult that source directly. This site is not an emergency notification service.
